赛诺菲印度公司获得CDSCO的RSV疫苗Beyfortus的上市许可。 Sanofi India receives marketing authorization for RSV vaccine Beyfortus from CDSCO.

赛诺菲印度公司获得RSV疫苗Beyfortus的上市许可，该疫苗可预防新生儿、婴儿和24个月以下儿童的下呼吸道疾病。 Sanofi India gains marketing authorization for RSV vaccine, Beyfortus, preventing lower respiratory tract disease in newborns, infants, and children up to 24 months. 该疫苗含有单克隆抗体nirsevimab，于2024年6月10日获得CDSCO批准。 The vaccine contains monoclonal antibody nirsevimab, approved by CDSCO on June 10, 2024. Beyfortus已经在欧盟、美国、中国和日本获得批准。 Beyfortus has already received approvals in the EU, US, China, and Japan.